Every material Form 8-K Inmune Bio, Inc. has filed with the SEC since September 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
INmune Bio agreed to sell 3,000,000 shares at $1.50 each in a registered direct offering to a single investor, with gross proceeds expected to be about $4.5 million before placement agent fees and expenses. The company also issued unregistered warrants for up to 3,000,000 shares at $1.65 per share, so the deal adds potential dilution for existing shareholders. The company said it intends to use the net proceeds for working capital and general corporate purposes.
3,000,000 common shares sold at $1.50 per share, with gross proceeds of about $4.5 million expected before fees
Unregistered warrants for up to 3,000,000 shares at $1.65 per share, first exercisable April 27, 2027 and expiring April 27, 2032
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Closing expected on or about October 29, 2026, subject to customary conditions
INmune Bio said it submitted its final pre-Marketing Authorisation Application package for Ebstrocel to the UK MHRA on October 20, 2026, and revised its plan to a full application in February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also signed a Master Services Agreement with Uniphar Durbin Ireland Limited to support international access and distribution, starting with named-patient access in selected European countries and the Middle East and North Africa. The filing does not disclose any financial terms of the Uniphar agreement or any revenue expectations.
Final pre-MAA package submitted to the UK MHRA on October 20, 2026; full MAA submission targeted for early February 2027
Company believes the revised approach could bring potential UK approval forward by approximately six weeks; MHRA response expected three to six months after submission
U.S. Biologics License Application planned for the second quarter of 2027, subject to FDA feedback from a Type B meeting request
Uniphar agreement initially targets named-patient access in selected European countries and MENA; no financial terms disclosed
INmune Bio's board increased its size to seven directors and appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, with both also joining the Nominating and Corporate Governance Committee. The company says the appointments add rare-disease commercialization and business-development experience as it prepares its Ebstrocel candidate for potential commercialization.
Board set at seven directors; Clark and Sapirstein appointed on September 8, 2026, serving until the next annual election
Each director to receive an option to purchase 100,000 shares of common stock, vesting in 36 equal monthly installments
Each director to receive an annual cash retainer of $50,000, paid quarterly in arrears
Clark is General Manager, U.S. Rare Diseases at Sanofi; Sapirstein is CEO of Cocrystal Pharma, Inc. (Nasdaq: COCP)
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Inmune Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →